Antineoplastic effect of 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in transgenic mice with retinoblastoma

Ilona Slusker Shternfeld, Jacques G.H. Lasudry, Richard J. Chappell, Soesiawati R. Darjatmoko, Daniel M. Albert

Research output: Contribution to journalArticle

24 Scopus citations

Abstract

Objective: To evaluate the in vivo efficacy and clinical toxic effects of the 1,25-dihydroxy-16-ene-23-yne-vitamin D3 analogue in β-luteinizing hormone-Tag (LHβ-Tag) transgenic mice with heritable retinoblastoma. Methods: Forty-two mice (8-10 weeks old), randomly assigned to experimental (n=21) or control (n=21) groups, received intraperitoneal injections of 0.05 μg of 1,25-dihydroxy-16-ene-23-yne-D3 in 0.5-mL mineral oil vehicle (experimental group) or 0.5 mL of mineral oil vehicle (control group) for 5 weeks. One experimental and 3 control animals died of injection-related trauma. Eyes were enucleated 1 week after treatment and were examined histologically in a masked fashion. Results: All experimental and control animals showed evidence of tumor. The tumors in the experimental mice showed a significantly smaller cross-sectional area (0.88±0.08 mm2) compared with that in the control mice (1.12±0.12 mm2) (P=.02). All mice completed the treatment and showed no clinical evidence of toxic effects. Conclusions: Tumors in transgenic mice with retinoblastoma treated with 1,25(OH)2-16- ene-23-yne-D3 showed a 21% smaller cross sectional area compared with that in the control mice, without producing clinically apparent toxic effects. This compound may be useful as adjunctive therapy in the treatment of retinoblastoma.

Original languageEnglish (US)
Pages (from-to)1396-1401
Number of pages6
JournalArchives of ophthalmology
Volume114
Issue number11
DOIs
StatePublished - Nov 1996

    Fingerprint

ASJC Scopus subject areas

  • Ophthalmology

Cite this